Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibandronate for Osteoporosis in HIV-Infected Patients
NCT00662077Phase 4Withdrawn
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ibandronate in osteoporosis (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoint: Increase in lumbar (L2-4) and femoral (trochanter, femur neck, total femur and hip) t-score bone mineral density at 96 weeks. Status: withdrawn.
02
Drugs
ibandronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00662077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662077.